Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
To expedite progress with your research on small molecule drugs, it is essential to collaborate with a solutions provider who possesses an in-depth understanding of the challenges and possibilities it presents. Alfa Cytology has a proven track record of successfully identifying small molecules with promising development potential, having delivered more than 50 compounds to our clients.
About 80% of approved medications consist of small molecules, organic compounds with low molecular weight. Researchers explore novel perspectives on leukemia development to uncover new drugs, enabling the design of interventions to hinder or reverse disease progression. The drug discovery process involves identifying potential drugs, synthesizing, characterizing, screening, and assessing therapeutic effectiveness.
Fig. 1. Stages of drug discovery and development process. (Deore, A.B. et al., 2019)
Small molecule drugs are compounds with low molecular weight. Due to their small size and good chemical properties, small-molecule drugs are well suited for entering the gastrointestinal tract and quickly being absorbed into the bloodstream. In addition, they can easily cross cell membranes to play a therapeutic role. Alfa Cytology provides comprehensive small molecule drug development services, including but not limited to the following.
Our range of services encompasses target discovery and validation. We have achieved notable success in identifying numerous novel targets for leukemia treatment, facilitating the design of targeted therapies.
High-Throughput Drug Screening
Our services offer high-throughput screening capabilities, allowing for the rapid testing of a vast number of compounds to identify those that modulate the activity of biological targets. We possess an extensive library of over one million compounds available for hit identification.
Our Hit-to-Lead Services provide comprehensive support and expertise in the crucial transition from hit compounds to lead candidates in drug discovery. We offer a range of services designed to optimize and advance promising hits towards becoming viable leads for further development.
With our expertise in medicinal chemistry, computer-aided drug design, pharmacokinetics, ADME/DMPK, we provide customer support for optimal compound design, aiming to discover the most promising candidate compounds.
The effective treatment of leukemia is profoundly hindered by the presence of drug resistance, presenting a substantial challenge. Given our comprehensive understanding of the mechanisms underlying leukemia drug resistance, we possess extensive experience in developing innovative therapeutic strategies, offering impactful solutions for your project.
Alfa Cytology offers a wealth of drug development data, enabling an understanding of why each stage of molecular development requires customized solutions. Our tailored solutions assist our clients in identifying new approaches to enhance research design and anticipate challenges throughout the development process. Contact us to learn how we can provide you with the services.
Reference